Stock Market Reviews

CRL (Charles River Laboratories International, Inc.) News

Get the latest news, insights, and market updates on CRL (Charles River Laboratories International, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Drug Development Inputs & Services Stocks Q3 Teardown: Charles River Laboratories (NYSE:CRL) Vs The Rest
  Looking back on drug development inputs & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
  Nov 17, 2025 - $CRL
• Charles River Laboratories to Present at Jefferies Global Healthcare Conference
  WILMINGTON, Mass., November 17, 2025--Charles River Laboratories to Present at Jefferies Global Healthcare Conference
  Nov 17, 2025 - $CRL
• 5 Must-Read Analyst Questions From Charles River Laboratories’s Q3 Earnings Call
  Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing challenges in the biotech funding environment, which dampened demand from smaller clients, and the loss of a major commercial customer in the Manufacturing segment. CEO James Foster explained that “client demand has stabilized,” but acknowledged lingering end market uncertainty, particularly among mid-
  Nov 12, 2025 - $CRL
• Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia
  Nov 11, 2025 - $CRL
• 3 Healthcare Stocks We Approach with Caution
  From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 7.5% gain for healthcare stocks has fallen short of the S&P 500’s 15.3% rise.
  Nov 10, 2025 - $CRL
• Charles River Labs (CRL) Is Down 6.7% After Strategic Overhaul and $1B Buyback Plan Announced
  In the past week, Charles River Laboratories International announced a major strategic overhaul following third-quarter results, including plans to divest underperforming businesses totaling about 7% of revenue, ramping up cost-saving measures expected to save US$70 million annually by 2026, and adopting a new US$1 billion share repurchase authorization. This move signals an accelerated effort to sharpen business focus and enhance shareholder value amid continued demand challenges and...
  Nov 8, 2025 - $CRL
• Charles River Labs (CRL): Assessing Valuation Following Recent Volatility and Share Price Recovery
  Charles River Laboratories International (CRL) shares edged up slightly, with investors watching for updates that could guide the laboratory services provider's outlook. The stock has moved 1% higher over the past month, reflecting a modest uptick in sentiment. See our latest analysis for Charles River Laboratories International. Charles River Laboratories International's share price has experienced some volatility, rising nearly 15% over the past quarter, while the 1-year total shareholder...
  Nov 7, 2025 - $CRL
• CRL Q3 Deep Dive: Portfolio Streamlining and End Market Stabilization Shape Outlook
  Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
  Nov 6, 2025 - $CRL
• Charles River (CRL) Q3 2025 Earnings Transcript
  This morning, I am joined by James Foster, Chair, President, and Chief Executive Officer, and Mike Nell, Senior Vice President, Interim Chief Financial Officer, and Chief Accounting Officer. Following the presentation, they will respond to questions.
  Nov 6, 2025 - $CRL
• Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
  While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
  Nov 5, 2025 - $CRL